To get in touch with XenTech, simply fill out the form below.
Subscribe to Supplier
XenTech to bring New Tumor Models and Insights to International Cancer Summit
Evry, France: – Biotech and contract research organisation XenTech is to bring significant results from its recent preclinical oncological research to the world’s leading cancer conference later this month.
The American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer are hosting their 2013 International Conference on Molecular Targets and Cancer Therapeutics (MTCT) in Boston on October 19-23.
The congress will bring together the oncological world’s leading academics, scientists, and pharmaceutical industry representatives to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.
XenTech is also expert in the preclinical evaluation of cancer drug efficacy and the omics-based identification of biomarkers and therapeutic targets. It is bringing to Boston significant new insights gained from its recently completed manual examination of next-generation sequencing data from its huge collect of tumor models. As a result it is now able to provide its sponsors with manually curated mutations for more than 70 of the most frequently occurring genes on the COSMIC cancer database.
Significant New Models
The Paris-based laboratory has also amassed one of the most characterized collections of patient-derived tumor xenograft (PDX) models, providing deeper understanding of tumor models, particularly in breast cancers. However, XenTech founder and Chief Scientific Officer Dr. Jean-Gabriel Judde, will tell the conference that the company’s panels have now expanded.
“While we are particularly known for our PDX panel and research leadership in breast cancer, we have also developed many new models in other indication areas, such as lung, melanoma, ovarian, endometrial and pancreatic tumors,” said Dr. Judde.
“We are particularly excited about our recent Renal Cell Carcinoma PDX panel, which closely matches biological features of patient tumors for each aspect of phenotypic RCC characteristics including histology, gene expression, genomics and drug response,” the XenTech President added.
XenTech has attended every MTCT Conference since 2010. In the year since the Dublin Conference, the company has also made strong progress in developing bioluminescent spontaneously metastatic PDX models that it is keen to share with fellow scientists.
Dr. Judde will lead the XenTech team at Booth 208 in the Hynes Convention Centre, ready to share knowledge and insights on projects of mutual interest.
“Xentech is now ready to share its strong scientific expertise in the field of oncology, anti-cancer drug efficacy assessment and biomarker discovery to foster the drug development of our sponsors and reduce the rate of attrition in drug development,” said Dr. Judde.
XenTech hopes that Dr. Judde’s presence at the Boston conference will provide unique opportunities for collaborators and partners to address scientific questions at high level and to acquire strategic insights.
XenTech is inviting MTCT delegates who wish to confer with Dr. Judde to contact the company in advance of the event to set up meetings.
XenTech is an innovative biotech/CRO company specializing in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX). PDX closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.
XenTech has assembled one of the world’s most impressive collections of PDX models that are extensively characterized and associated to molecular data, including gene expression, copy number data, and manually curated mutations. Its preclinical platform is of considerable value for translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine. XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.
XenTech is known worldwide for its renowned oncology translational platform, its unique panel of patient-derived breast cancer xenografts and its extremely experienced scientific team.
About Molecular Targets and Cancer Therapeutics Conference 2013
Hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC), the 2013 Molecular Targets and Cancer Therapeutics conference has become established since 2010 as the world’s leading summit on cancer research.
Last year’s AACR-NIC-EORTC congress was held in Dublin and brought together more than 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe.
This year’s congress will take place at the Hynes Convention Centre in Boston, Massachusetts, USA from 19th to 23rd of October 2013 and will once again discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.
The 2013 congress will review advances over the past few years, during which numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer.
Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development and the execution of large, prospective, randomized, multicenter cancer clinical trials.
The conference will consider a corresponding joint and global approach, enabling early and most effective exchange of information.
Sabrina Serpillon, Head of Business Development
Tel: +33 1 60 87 89 80
For more information about preclinical tumor models, please contact XenTech directly.